Group 1: Business Operations - The company's plant protection business has reached a bottom in inventory reduction, and future operations are expected to stabilize [1] - The company maintains a long-term partnership with clients, focusing on a CDMO business model for the production of advanced intermediates [1] - The company plans to invest $200 million in the construction of its Malaysia base, with the first phase expected to be completed by the end of 2026 [4] Group 2: New Energy Sector - The company primarily sells LiFSI, cathode materials, and electrolyte products, with plans to strengthen existing products in 2026 [3] - The lithium hexafluorophosphate product is undergoing technical improvements, with commercialization expected in 2026 [3] - The company aims to expand its new energy product range and market presence, leveraging its R&D and production capabilities [3] Group 3: Pharmaceutical Business - The pharmaceutical sector has shown steady growth, with a focus on large clients and CDMO business models [5] - The company is actively expanding its client base and developing new projects in the pharmaceutical sector [5] - The company is investing in R&D to enhance its technical capabilities, exploring new areas such as amino acids and peptides [6] Group 4: Client Dependency and Market Strategy - The company acknowledges a high client concentration but emphasizes the importance of maintaining strong relationships with existing clients while seeking new ones [6][7] - The company believes that focusing on existing clients and expanding the customer base fosters mutual trust and sustainable cooperation [7] Group 5: Financial Outlook and Capital Expenditure - The company has no immediate plans for capital operations in the secondary market, focusing instead on investments in its coastal and Malaysian bases [7] - The net cash flow from operating activities for the first three quarters of 2025 is approximately 1 billion, sufficient to support planned capital expenditures [7] - Exchange rate gains and losses are expected to continue affecting net profits, with significant USD revenues and hedging activities in place [7]

Core Viewpoint - The company is expanding its pharmaceutical business by diversifying into emerging sectors while consolidating its established small molecule CDMO services [1] Group 1: Business Expansion - The company is focusing on expanding its service areas in the pharmaceutical sector [1] - It is investing heavily in new business areas such as peptide products, radiopharmaceutical-related CDMO, animal health CDMO, generic drug intermediates and APIs, and cosmetic raw materials [1] Group 2: Technical Capabilities - The company's technical capabilities have evolved from traditional small molecules to include amino acids, peptides, PROTAC/ADC linkers, and oligonucleotides [1] - It has experience in delivering from linker grams to hundreds of grams, enabling the design and optimization of synthetic routes for clients [1] - This capability supports the transition of early clinical projects [1]